Trademark Overview
On Wednesday, September 1, 2021, a trademark application was filed for IMMUNOSTASIS with the United States Patent and Trademark Office. The USPTO has given the IMMUNOSTASIS trademark a serial number of 97007239. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Thursday, December 29, 2022. This trademark is owned by Statera Biopharma, Inc.. The IMMUNOSTASIS trademark is filed in the Pharmaceutical Products, Education & Entertainment Services, and Computer & Software Services & Scientific Services categories with the following description:
Educational services, namely, conducting classes, seminars, conferences, and workshops and distributing printed course materials in conjunction therewith; providing on-line journals, namely, blogs in the medical, pharmaceutical and health fields
Pharmaceutical preparations and compounds for use in immune modulation, oncology, infectious diseases; pharmaceutical preparations for the treatment or prevention of immune-mediated diseases, Crohn's disease, multiple sclerosis, viral infections, HIV/AIDS, cancer, cell growth related disorders, cell proliferation related disorders, inflammatory diseases, ulcerative diseases, autoimmune diseases, autism, dermatological, cardiovascular, hematological, bone, respiratory, central nervous system, endocrinological, circulatory, gastroenterological, stomach, digestive, hormonal, diabetic, muscular, rheumatic, immune system, ocular and metabolic diseases and disorders; anti-infectives; anti-inflammatories; vaccines; pharmaceutical preparations and compounds for reducing side effects in cancer treatment; pharmaceutical preparations and compounds for stimulating the immune system in an immuno-compromised patient; dietetic substances for medical purposes, namely, nutritional, vitamin and mineral ...
Pharmaceutical and therapeutics research and development services for systemically delivered, locally active immune balancing conjugates, small molecules and peptides; research and development of systemically delivered, locally active immune balancing conjugates, small molecules and peptides in the pharmaceutical, therapeutics and biotechnology fields; research and product development of systemically delivered, locally active immune balancing conjugates, small molecules and peptides in the field of human therapeutics; research services using a platform of biological research tools and techniques for use in the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases and fibrotic diseases with systemically delivered, locally active immune balancing conjugates, small molecules and peptides; pharmaceutical product development of systemically delivered, locally active immune balancing conjugates, small molecules and peptides
